2012
PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer
Su D, Xu H, Feng J, Gao Y, Gu L, Ying L, Katsaros D, Yu H, Xu S, Qi M. PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer. Journal Of Translational Medicine 2012, 10: 31. PMID: 22369209, PMCID: PMC3305474, DOI: 10.1186/1479-5876-10-31.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overApoptosisApoptosis Regulatory ProteinsBlotting, WesternCalcium-Binding ProteinsCarcinoma, Ovarian EpithelialCell CycleCell Line, TumorCell ProliferationDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesGene SilencingGenetic VectorsHumansKaplan-Meier EstimateLentivirusMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisNeoplasms, Glandular and EpithelialOvarian NeoplasmsRNA, MessengerRNA, Small InterferingStatistics, NonparametricTransfectionConceptsEpithelial ovarian cancerProgression-free survivalOvarian cancer progressionOvarian cancer cellsOvarian cancerFree survivalOverall survivalIndependent predictorsKaplan-Meier survival analysisEpithelial ovarian cancer tissuesMetastatic ovarian cancer cellsCancer progressionPDCD6 expressionResidual tumor sizeClinical pathological factorsEpithelial ovarian cancer correlatesCancer cellsOvarian cancer correlatesOvarian cancer tissuesHistologic typeClinical progressionTumor sizeDisease stageTumor gradeCancer correlates
2010
A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.Peer-Reviewed Original ResearchConceptsOvarian cancerKRAS-variantOC patientsCancer riskRisk of OCIndependent case-control analysesCase-control studyOvarian cancer syndromeCase-control analysisFamily membersAdvanced diseaseWomen's cancersRisk factorsBRCA2 mutationsHBOC patientsOC casesIndependent cohortHBOC familiesHereditary breastSolid tumorsCancer syndromesKRAS oncogeneVariant allelesPatientsCancer
2009
Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel
Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009, 115: 2453-2463. PMID: 19322891, DOI: 10.1002/cncr.24282.Peer-Reviewed Original ResearchConceptsHigh stathmin expressionBetaIII-tubulinOvarian cancerTreatment responseOverall survivalStathmin expressionDisease progressionPaclitaxel treatmentResidual tumor sizePlatinum-based chemotherapyEpithelial ovarian cancerOvarian cancer patientsFresh tumor samplesMessenger RNA expressionBetaIII-tubulin expressionCytoreductive surgeryPatient agePolymerase chain reaction analysisPatient survivalTumor sizeDisease stagePlatinum chemotherapyPoor prognosisUnfavorable prognosisCancer patients
2007
ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy
Smith S, Su D, de la Longrais I, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D. ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy. Journal Of Clinical Oncology 2007, 25: 5172-5179. PMID: 18024864, DOI: 10.1200/jco.2007.11.8547.Peer-Reviewed Original ResearchConceptsExcision repair cross-complementation group 1High ERCC1 expressionOvarian cancer patientsERCC1 expressionC genotypeDisease progressionGreater riskCancer patientsTreatment responseCodon 118Postoperative platinum-based chemotherapyEpithelial ovarian cancer patientsLow ERCC1 expressionSurvival of patientsPlatinum-based chemotherapyEpithelial ovarian cancerERCC1 mRNA expressionCombination of platinumERCC1 genotypePlatinum chemotherapyPoor prognosisOvarian cancerPaclitaxel treatmentGroup 1T genotypeHypermethylation of let-7a-3 in Epithelial Ovarian Cancer Is Associated with Low Insulin-like Growth Factor-II Expression and Favorable Prognosis
Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in Epithelial Ovarian Cancer Is Associated with Low Insulin-like Growth Factor-II Expression and Favorable Prognosis. Cancer Research 2007, 67: 10117-10122. PMID: 17974952, DOI: 10.1158/0008-5472.can-07-2544.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor IIPossible epigenetic regulationLet-7 regulationEpithelial ovarian cancerLet-7aRole of miRNAsActivity of mRNAPromoter CpG island methylationCpG island methylationTumor suppressor geneIGF-II expressionMiRNA genesSmall RNAsEpigenetic regulationOvarian cancerDNA methylationCpG islandsMethylation-specific PCRReal-time reverse transcription PCRReverse transcription-PCRReal-time methylation-specific PCRSuppressor geneIsland methylationMethylationMiRNA expressionIGF-I in epithelial ovarian cancer and its role in disease progression
Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H, Yu H. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007, 25: 346-354. PMID: 18236213, DOI: 10.1080/08977190701838402.Peer-Reviewed Original ResearchConceptsIGF-I transcriptsDisease progressionOvarian cancerTumor progressionEpithelial ovarian cancer patientsIGF-I mRNA expressionInsulin-like growth factorParacrine/autocrine regulationIGF-I activityEpithelial ovarian cancerIGF-I actionOvarian cancer patientsFresh tumor samplesIGF-I expressionIGF-I mRNAOvarian cancer progressionEnzyme-linked immunosorbentParacrine/autocrineTotal IGFFree IGFClinicopathologic featuresCA polymorphismCancer patientsReal-time PCRElevated risk
2006
Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer
WILEY A, KATSAROS D, FRACCHIOLI S, YU H. Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210-218. PMID: 16445635, DOI: 10.1111/j.1525-1438.2006.00299.x.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsy, NeedleCarcinomaCohort StudiesDNA MethylationFemaleHumansImmunohistochemistryInsulin-Like Growth Factor Binding Protein 3Multivariate AnalysisNeoplasm StagingOvarian NeoplasmsOvariectomyProbabilityPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsSensitivity and SpecificitySurvival RateConceptsIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic marker
2005
Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival
Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecologic Oncology 2005, 100: 330-337. PMID: 16199080, DOI: 10.1016/j.ygyno.2005.08.035.Peer-Reviewed Original ResearchConceptsOvarian cancer treatmentDisease progressionGSTP1 genotypesGST polymorphismsPrimary epithelial ovarian cancerCox proportional hazards regressionFunctional polymorphismsGSTP1 Ile/IleCancer treatmentGSTP1 Ile/ValGlutathione S-transferase polymorphismsGSTM1 null patientsPost-operative chemotherapySubgroup of patientsProportional hazards regressionEpithelial ovarian cancerOvarian cancer survivalEffect of chemotherapyOvarian cancer prognosisOvarian cancer progressionVal/ValIle/IleIle/ValOverall survivalTumor characteristics
2004
Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer
Katsaros D, Cho W, Singal R, Fracchioli S, de la Longrais I, Arisio R, Massobrio M, Smith M, Zheng W, Glass J, Yu H. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecologic Oncology 2004, 94: 685-692. PMID: 15350359, DOI: 10.1016/j.ygyno.2004.06.018.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancer prognosisOvarian cancerP16 methylationMethylation-specific PCRCancer prognosisPrimary epithelial ovarian cancerResidual tumor sizePromoter methylationRegression survival analysisOvarian cancer progressionFresh frozen tumor tissueP16 promoter methylationFrozen tumor tissueAdvanced diseaseNegative patientsOverall survivalPatient agePositive patientsPathological variablesTumor sizeDisease stageHistological gradeAggressive tumorsDisease progression
2001
IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival
Katsaros D, Yu H, Levesque M, Danese S, Genta F, Richiardi G, Fracchioli S, Khosravi M, Diamandi A, Gordini G, Diamandis E, Massobrio M. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. European Journal Of Cancer 2001, 37: 478-485. PMID: 11267857, DOI: 10.1016/s0959-8049(00)00423-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor Binding Protein 3Middle AgedNeoplasm ProteinsNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisRisk FactorsConceptsIGFBP-3 levelsInsulin-like growth factorLower IGFBP-3 levelsEpithelial ovarian carcinomaIGFBP-3Overall survivalPatient survivalOvarian carcinomaGrowth factorUnfavourable prognostic featuresIGFBP-3 concentrationsClinico-pathological featuresEpithelial ovarian cancerPatients' overall survivalResponse of patientsOvarian cancer progressionAnti-apoptotic actionClinicopathological featuresPathological variablesPrognostic featuresResidual tumorDisease progressionOvarian cancerDisease prognosisAverage age
1999
Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou E, Levesque M, Katsaros D, Angelopoulou K, Yu H, Genta F, Arisio R, Massobrio M, Bharaj B, Diamandis E. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. Anticancer Research 1999, 19: 749-56. PMID: 10216487.Peer-Reviewed Original ResearchConceptsP53 protein accumulationOvarian carcinomaP53 abnormalitiesP53 mutationsP53 proteinMissense point mutationsPrimary epithelial ovarian carcinomaEpithelial ovarian carcinomaGrade 3 lesionsCM-1 antibodyP53 protein overexpressionP53 exons 5Exon 5Unfavorable prognosisMutant p53 proteinP53 alterationsSerous histotypeClinical valueStage IIIDO-1Most malignanciesImmunofluorometric assayCarcinomaTumor tissueProtein accumulation
1997
NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN
Diamandis E, Yu H. NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN. Urologic Clinics Of North America 1997, 24: 275-282. PMID: 9126224, DOI: 10.1016/s0094-0143(05)70373-6.Peer-Reviewed Original ResearchMeSH KeywordsAmniotic FluidBreastBreast NeoplasmsFemaleHumansMaleOvarian NeoplasmsProstate-Specific AntigenUrethraConceptsNonprostatic tissuesProstate-specific antigenBreast nipple aspirate fluidBreast cancer risk assessmentPSA gene expressionBreast cancer cytosolsHigher PSA concentrationsBreast cancer prognosisRegulation of PSAPotential clinical utilityCancer risk assessmentMicrograms/LNonprostatic sourcesPSA regulationAndrogen excessSerum PSAMicrograms/L.Breast secretionsAspirate fluidSeminal plasmaPSA productionPSA-ACT complexClinical utilityCancer cytosolsProstatic tissue
1996
Circulating antibodies against p53 protein in patients with ovarian carcinoma
Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis E. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Cancer 1996, 78: 2146-2152. PMID: 8918407, DOI: 10.1002/(sici)1097-0142(19961115)78:10<2146::aid-cncr15>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsAntibody-positive patientsOvarian carcinomaP53 antibodiesP53 autoantibodiesPositive patientsSuch antibodiesMultivariate analysisPatient disease-free survivalKaplan-Meier survival curvesSerum p53 antibodiesTumor p53 overexpressionDisease-free survivalOlder patient ageSubset of patientsTumor histologic typeOverall patient survivalSera of patientsFrequent molecular eventUnits/LFree survivalNegative patientsOverall survivalPatient ageSuch autoantibodiesAntibody levels
1995
Prostate-specific antigen and lack of specificity for prostate cells
Diamandis E, Yu H. Prostate-specific antigen and lack of specificity for prostate cells. The Lancet 1995, 345: 1186. PMID: 7536878, DOI: 10.1016/s0140-6736(95)91021-2.Peer-Reviewed Original ResearchExpression of the prostate-specific antigen gene by a primary ovarian carcinoma.
Yu H, Diamandis E, Levesque M, Asa S, Monne M, Croce C. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Research 1995, 55: 1603-6. PMID: 7536128.Peer-Reviewed Original ResearchMeSH KeywordsBase SequenceBlotting, SouthernBudd-Chiari SyndromeChromatography, High Pressure LiquidDNA PrimersDNA, NeoplasmFemaleGene ExpressionGlucocorticoidsHumansImmunohistochemistryLiver TransplantationMiddle AgedMolecular Sequence DataOvarian NeoplasmsPolymerase Chain ReactionProstate-Specific AntigenConceptsProstate-specific antigenPrimary ovarian carcinomasLiver transplantationOvarian tumorsOvarian carcinomaPSA geneProstate-specific antigen geneBreast carcinoma cell linesCarcinoma cell linesPSA cDNAProstate tissueTumor tissueTumorsEpithelial cellsTranscription-PCRWhole coding sequencePatientsTransplantationCarcinomaCell linesImmunohistochemistryAntigen geneTissue culture experimentsTissueDNA sequencingMutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
Levesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75: 1327-1338. PMID: 7882283, DOI: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p.Peer-Reviewed Original ResearchConceptsEpithelial ovarian carcinomaOvarian carcinomaMutant p53 proteinResidual tumorHistologic gradeOvarian cancerP53 proteinCancer relapseMutant p53 protein overexpressionLonger disease-free survivalKaplan-Meier survival curvesPostsurgical residual tumorDisease-free survivalEarly-stage diseaseSubset of patientsLow histologic gradeMutant p53 protein accumulationAdvanced-stage cancerDifferent clinical stagesP53-negative tumorsP53-positive tumorsP53 protein overexpressionPoor patient outcomesAnti-p53 antibodiesP53 protein accumulation
1994
Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary
Yu H, Diamandis E, Levesque M, Sismondi P, Zola P, Katsaros D. Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. Journal Of Clinical Laboratory Analysis 1994, 8: 251-253. PMID: 7523638, DOI: 10.1002/jcla.1860080412.Peer-Reviewed Original ResearchConceptsProstate-specific antigenMetastatic ovarian cancerPrimary breast tumorsBreast tumorsOvarian cancerSpecific antigenPrimary ovarian cancer tumorsFavorable prognostic indicatorOvarian cancer tumorsMetastatic sitesTumor metastaticPrognostic indicatorBreast cancerPSA productionEctopic productionTumorsSteroid hormonesCancer tumorsCancerPatientsAntigenTreatmentLow levelsHigh levelsMetastatic